Research
Hormonal
Each unit increase in baseline BMI is associated with a statistically significant decrease in health utility scores, indicating that higher obesity severity correlates with lower quality of life.
Higher BMI is consistently linked to lower health utility scores. Treating obesity with semaglutide 2.4 mg can reverse this trend, improving quality of life.
GoodRefutesHIGH confidence
A 1-unit increase in BMI was associated with a utility loss of 0.0075 ((cid:1)0.0089 to (cid:1)0.0062) for the FAS population, while controlling for demographic and clinical parameters.
Why this rating
Based on multiple linear regression controlling for demographics and clinical parameters in a large RCT population.
Source
Treatment effect of semaglutide 2.4 mg on health‐related quality of life from <scp>STEP</scp> 1 <scp>SF‐6D</scp> derived from <scp>SF</scp> ‐36 with Australian weights
Pavol Kral et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15426
rct · n=1961Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg administered once weekly for 68 weeks significantly improves health-related quality of life (HRQoL) utility scores compared to placebo in adults with overweight or obesity.Good
- Higher baseline BMI and the presence of symptomatic comorbidities (specifically knee osteoarthritis or obstructive sleep apnoea) are associated with greater improvements in health utility scores following semaglutide 2.4 mg treatment.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →